Philip Meijnen
Amsterdam University Medical Centers, Cancer Center Amsterdam
Papers
3
Total Citations
39
H-Index
3
About
Philip Meijnen is a leading clinical researcher in urologic oncology, with a primary focus on improving outcomes for men with biochemically recurrent prostate cancer. His work centers on the integration of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) into the management of patients undergoing salvage radiation therapy after radical prostatectomy. Meijnen’s major contribution lies in demonstrating that PSMA PET/CT, with its superior diagnostic accuracy over conventional imaging, is associated with improved oncological outcomes in this setting—a finding from his highly cited 2022 study (30 citations). He has also developed and internally validated a novel nomogram to predict salvage therapy outcomes specifically for patients without metastases on PSMA PET/CT, a practical tool for clinical decision-making. By assessing predictors of short-term response and refining patient selection, his research directly addresses the challenge of biochemical recurrence. With a growing citation impact and a focus on translating advanced imaging into tangible survival benefits, Meijnen’s work is shaping the standard of care for post-prostatectomy salvage treatment.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3